Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
5
×
biotech
clinical trials
fda
5
×
life sciences
national blog main
eli lilly
indiana blog main
indiana top stories
teva pharmaceutical
boston blog main
calcitonin gene-related peptide
chronic migraine
migraine research foundation
national
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
drugs
episodic migraine
eptinezumab
erenumab
fremanezumab
galcanezumab
indiana
lasmiditan
migraine
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
What
approval
5
×
drug
fda
migraine
new
won
class
developed
amgen
decades
eli
lilly
medicines
nod
pain
starts
acute
addresses
amgen’s
announced
approved
arguments
big
candidates
carries
causes
commercialized
companies
competitors
condition
decision
drugs
europe
european
friday
gets
giant
giving
head
headache
Language
unset
Current search:
approval
×
fda
×
amgen
×
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines